A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity | MicrobiomeTrials
A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-06-19Est. Completion: 2027-02
Enrollment target: 150 participants
Locations
CenExel Phoenix, Chandler, Arizona, United States
CenExel Anaheim, Anaheim, California, United States
CenExel Hollywood, Hollywood, Florida, United States
CenExel Tampa, Tampa, Florida, United States
CenExel Atlanta, Atlanta, Georgia, United States
CenExel Decatur, Decatur, Georgia, United States
CenExel Savannah, Savannah, Georgia, United States
CenExel SLC, Salt Lake City, Utah, United States
Other microbiome trials you might be interested in